Evidence map›Paper›PMID 37429670›Full record

ArticleLupus science & medicine2023

Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA.

Hermine I Brunner, Aisha Vadhariya, Christina Dickson, Wallace Crandall, Casey Kar-Chan Choong, Julie A Birt, Nicolino Ruperto, Athimalaipet V Ramanan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus science & medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Observational
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Revisiting Childhood-Onset Systemic Lupus Erythematosus.Turkish archives of pediatrics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Hermine I BrunnerCincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio, USA.ORCID 0000-0001-9478-2987
Aisha VadhariyaEli Lilly and Company, Indianapolis, Indiana, USA vadhariya_aisha@lilly.com.ORCID 0000-0002-1811-5370
Christina DicksonEli Lilly and Company, Indianapolis, Indiana, USA.
Wallace CrandallEli Lilly and Company, Indianapolis, Indiana, USA.
Casey Kar-Chan ChoongEli Lilly and Company, Indianapolis, Indiana, USA.
Julie A BirtEli Lilly and Company, Indianapolis, Indiana, USA.
Nicolino RupertoIRCCS Istituto Giannina Gaslini, UOC Gaslini Trial Centre/Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genova, Italy.ORCID 0000-0001-8407-7782
Athimalaipet V RamananBristol Royal Hospital for Children, Bristol, UK.
Eli Lilly (United States) · USBristol Royal Hospital for Children · GBCincinnati Children's Hospital Medical Center · USIstituto Giannina Gaslini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess real-world treatment regimens and patterns in childhood-onset SLE (cSLE) and adult-onset SLE (aSLE) cohorts, including similarities in treatments, duration of use and adherence.

methodsThis retrospective study utilised data from Merative L.P. MarketScan Research Databases (USA). Index date was the date of first SLE diagnosis (2010-2019). Patients aged <18 years (cSLE) and ≥18 years (aSLE) at index date with confirmed SLE diagnosis and ≥12 months continuous enrolment during pre-index and post-index periods were included. The cohorts were stratified based on the presence (existing) or absence (new) of pre-index SLE. Primary outcomes (post-index period) included treatment regimens (all patients), and adherence (proportion of days covered (PDC)) and discontinuation of therapies initiated within 90 days of diagnosis (new patients). Univariate comparisons between cSLE and aSLE cohorts were performed using Wilcoxon rank-sum and χ

resultscSLE cohort included 1275 patients (mean age=14.1 years) and aSLE cohort included 66 326 patients (mean age=49.7 years). Antimalarials and glucocorticoids were commonly used among new (cSLE=64.4%/62.0%; aSLE=51.8%/49.7%) and existing (cSLE=68.6%/58.9%; aSLE=63.8%/51.3%) patients in both cohorts. Median oral glucocorticoid dose (prednisone equivalent) was higher in cSLE vs aSLE (new=22.1 vs 14.0 mg/day; existing=14.4 vs 12.3 mg/day; p<0.05). Mycophenolate mofetil use was higher in patients with cSLE vs aSLE (new=26.2% vs 5.8%; existing=37.6% vs 11.0%; p<0.0001). Compared with aSLE, more patients used combination therapies in cSLE (p<0.0001). Median PDC was higher in cSLE vs aSLE for antimalarials (0.9 vs 0.8; p<0.0001) and oral glucocorticoids (0.6 vs 0.3; p<0.0001). Treatment discontinuation was lower in cSLE vs aSLE for antimalarials (25.0% vs 33.1%; p<0.0001) and oral glucocorticoids (56.6% vs 71.2%; p<0.0001).

conclusionsManagement of cSLE and aSLE includes the same medication classes; differences include more intensive use of therapy in cSLE, warranting the need for approved safe medications for cSLE.

Indexed as

AntimalarialsLupus Erythematosus, SystemicAdolescentAdultChildGlucocorticoidsHumansMiddle AgedPrednisoneRetrospective StudiesUnited StatesAntimalarialsGlucocorticoidsPrednisoneAutoimmune diseasesHealthcare outcome assessmentSystemic lupus erythematosus

Identifiers

PMID37429670
PMCPMC10335505
OpenAlexW4383871975

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.